全髋关节置换术后假体周围骨折患者的全身性骨质疏松与骨量减少
本研究回顾171例全髋关节置换术后Vancouver B2/B3型股骨假体周围骨折患者,发现94%骨折由站立高度跌倒导致,骨质疏松诊断率从骨折前20%升至骨折后39%,但FRAX评分、骨密度检测和双膦酸盐治疗仍存在明显缺口。
要点
- 94%的假体周围骨折由站立高度跌倒导致,符合骨质疏松定义事件。
- 骨质疏松诊断率从骨折前20%升至骨折后39%(P < .001)。
- 仅16%患者最终接受年龄匹配的骨密度检测。
核心结论
- 多数全髋关节置换术后假体周围骨折为脆性骨折,符合骨质疏松诊断,但在诊断、筛查、内分泌随访和治疗方面仍存在重大缺口。
- 与非关节置换脆性骨折类似,假体周围骨折后需要系统性管理方法。
研究设计与样本
- 回顾性队列研究(证据等级III),纳入2000年至2018年单机构治疗的171例Vancouver B2型(109例)和B3型(62例)股骨假体周围骨折患者,均采用组配式带槽锥形柄治疗。
- 患者平均年龄75岁(范围35至94岁),50%为女性,平均体重指数29(范围17至60),平均随访11年(范围4至21年)。
主要发现
- 94%的骨折由站立高度跌倒导致,按定义符合骨质疏松诊断事件。
- 骨质疏松诊断率从骨折前20%升至骨折后39%(P < .001),骨量减少诊断率从13%升至24%(P < .001),任一诊断率从24%升至44%(P < .001)。
- 骨折前无患者记录FRAX评分,骨折后仅2%有评分;骨密度检测率骨折前21%、骨折后22%(P = .88),至末次随访仅16%接受年龄匹配的骨密度检测。
- 内分泌会诊比例从骨折前6%升至骨折后25%(P < .001),双膦酸盐治疗比例从骨折前19%升至骨折后25%(P = .08)。
关键数值与推荐
- 年龄匹配的骨密度检测定义为不晚于推荐年龄(女性65岁、男性70岁)后1年。
- 骨质疏松诊断率骨折前20% vs 骨折后39%(P < .001);骨量减少诊断率骨折前13% vs 骨折后24%(P < .001);任一诊断率骨折前24% vs 骨折后44%(P < .001)。
- FRAX评分记录率骨折前0% vs 骨折后2%;骨密度检测率骨折前21% vs 骨折后22%(P = .88);年龄匹配骨密度检测率16%。
- 内分泌会诊率骨折前6% vs 骨折后25%(P < .001);双膦酸盐治疗率骨折前19% vs 骨折后25%(P = .08)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most periprosthetic fractures following total hip arthroplasty (THA) are fragility fractures that qualify patients for osteoporosis diagnoses. However, it remains unknown how many patients were diagnosed who had osteoporosis before injury or received the proper evaluation, diagnosis, and treatment after injury. METHODS: We identified 171 Vancouver B2 (109) and B3 (62) periprosthetic femur fractures treated with a modular fluted tapered stem from 2000 to 2018 at 1 institution. The mean patient age was 75 years (range, 35 to 94), 50% were women, and the mean body mass index was 29 (range, 17 to 60). We identified patients who had osteoporosis or osteopenia diagnoses, a fracture risk assessment tool (FRAX), bone mineral density (BMD) testing, an endocrinology consult, and osteoporosis medications. Age-appropriate BMD testing was defined as no later than 1 year after the recommended ages of 65 (women) or 70 years (men). The mean follow-up was 11 years (range, 4 to 21). RESULTS: Falls from standing height caused 94% of fractures and thus, by definition, qualified as osteoporosis-defining events. The prevalence of osteoporosis diagnosis increased from 20% before periprosthetic fracture to 39% after (P < .001). The prevalence of osteopenia diagnosis increased from 13% before the fracture to 24% after (P < .001). The prevalence of either diagnosis increased from 24% before fracture to 44% after (P < .001). No patients had documented FRAX scores before fracture, and only 2% had scores after. The prevalence of BMD testing was 21% before fracture and 22% after (P = .88). By the end of the final follow-up, only 16% had received age-appropriate BMD testing. The proportion of patients who had endocrinology consults increased from 6% before the fracture to 25% after (P < .001). The proportion on bisphosphonate therapy was 19% before fracture and 25% after (P = .08). CONCLUSIONS: Although most periprosthetic fractures following THA are fragility fractures that qualify patients for osteoporosis diagnoses, there remain major gaps in diagnosis, screening, endocrinology follow-up, and treatment. Like nonarthroplasty fragility fractures, a systematic approach is needed after periprosthetic fractures. LEVEL OF EVIDENCE: Level III, retrospective cohort study.
引用
- Seward MW, Hannon CP, Yuan BJ, et al. Systemic Osteoporosis and Osteopenia Among Periprosthetic Fractures After Total Hip Arthroplasty. J Arthroplasty. 2024. PMID: 38852691. doi:10.1016/j.arth.2024.06.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。